Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma

NCT05460767 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

260

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors or Lymphoma

Interventions

BIOLOGICAL: IBI363

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.